Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Imatinib
Gleevec, RAD001, and Hydroxyurea · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pts receiving EIACDs |
| 2 | EXPERIMENTAL | Pts not receiving EIACDs |
| Name | Type | Description |
|---|---|---|
| Gleevec, RAD001, and Hydroxyurea | DRUG | Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues. |
Inclusion Criteria: * Pts w confirmed GBM, GS, AA, AO \& AOA are presenting in 1st, 2nd/3rd recurrence/relapse * Pts without tumor biopsy \<1 wk/surgical resection \<2 wks prior to starting study drug * For stratum of non-EIAED pts, each pts off all enzyme inducing anticonvulsants for \>2 wks prior...
Gleevec, also known as imatinib, is being studied for use in lung cancer and prostate cancer. It is an investigational small molecule in Phase 2 clinical development for these oncology indications. Gleevec is not approved for these uses and remains under clinical investigation.
Gleevec targets ABL1, BCR, KIT, and PDGFRB. It is a kinase inhibitor that acts on these molecular targets. This mechanism is relevant to its investigational use in oncology, including lung cancer and prostate cancer.
Gleevec is developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials of Gleevec, also known as imatinib, for oncology indications including lung cancer and prostate cancer.
Gleevec is in Phase 2 clinical development for lung cancer and prostate cancer. It is an investigational drug and has not been approved for these indications. Clinical trials are ongoing or completed to evaluate its safety and efficacy.
Gleevec has one completed Phase 2 trial, NCT00222144, which studied Gleevec and Taxotere in recurrent non-small cell lung cancer with 23 participants. Another completed trial, NCT00251225, studied imatinib and docetaxel in prostate cancer with 49 participants. Both were conducted in the United States.
Yes, Gleevec is the same as imatinib. The drug is known by both names, with imatinib being the generic name and Gleevec the brand name. Clinical trials may refer to it as either Gleevec or imatinib.